Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has earned an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $17.83.

Several brokerages recently weighed in on VYGR. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, August 20th. Wedbush lowered their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th.

Voyager Therapeutics Stock Down 3.6 %

VYGR stock opened at $6.79 on Thursday. The business’s fifty day simple moving average is $6.67 and its two-hundred day simple moving average is $7.83. Voyager Therapeutics has a twelve month low of $5.71 and a twelve month high of $11.72. The firm has a market cap of $369.34 million, a price-to-earnings ratio of -135.80 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The business had revenue of $29.58 million during the quarter, compared to the consensus estimate of $11.52 million. During the same quarter last year, the company earned ($0.51) earnings per share. Research analysts expect that Voyager Therapeutics will post -1.44 EPS for the current year.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at $500,525.82. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. increased its holdings in Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after purchasing an additional 1,300 shares during the period. Victory Capital Management Inc. boosted its position in shares of Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after purchasing an additional 1,630 shares during the period. SummerHaven Investment Management LLC lifted its position in Voyager Therapeutics by 2.5% during the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock worth $611,000 after acquiring an additional 1,921 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Voyager Therapeutics by 2.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock worth $925,000 after acquiring an additional 2,030 shares during the period. Finally, Federated Hermes Inc. lifted its position in Voyager Therapeutics by 0.5% during the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock worth $4,384,000 after acquiring an additional 2,638 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.